Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

20204,830 citationsJournal Articlebronze Open Access

Authors

Milton Packer · Imperial Valley College

Stefan D. Anker · British Heart Foundation

Javed Butler · British Heart Foundation

Gerasimos Filippatos · National and Kapodistrian University of Athens

Stuart Pocock · University of London

Peter E. Carson · British Heart Foundation

James L. Januzzi

Abstract

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 15, pp. 1413-1424

DOI: 10.1056/nejmoa2022190

Field-Weighted Citation Impact: 429.13